Performance of rotavirus vaccines in developed and developing countries

Clicks: 375
ID: 118827
2010
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The World Health Organization estimates that rotavirus diarrhea results in approximately half a million deaths and approximately 2.4 million hospitalizations in developing countries each year. Two live oral rotavirus vaccines, RotaTeq® (RV 5; Merck) and Rotarix® (RV 1; GlaxoSmithKline) with good eff …
Reference Key
v2010humanperformance Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jiang V;Jiang B;Tate J;Parashar UD;Patel MM;;
Journal human vaccines
Year 2010
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/20622508
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review humans pubmed abstract nih national institutes of health national library of medicine Incidence Diarrhea / epidemiology diarrhea / prevention & control gastroenteritis / prevention & control rotavirus infections / prevention & control* rotavirus vaccines / immunology* gastroenteritis / epidemiology rotavirus infections / epidemiology* rotavirus vaccines / administration & dosage* developing countries manish m patel developed countries pmid:20622508 pmc3322519 doi:10.4161/hv.6.7.11278 victoria jiang baoming jiang

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.